Back to mobile site

JPMorgan Starts Nuvation Bio Inc (NUVB) at Overweight

August 18, 2026 3:51 AM EDT Send to a Friend
JPMorgan analyst Priyanka Grover initiates coverage on Nuvation Bio Inc (NYSE: NUVB) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login